Eun‐Seok Park

593 citations
28 papers · 506 indexed · h-index 14
Topics
PARP inhibition in cancer therapy (3 papers)Cardiac Ischemia and Reperfusion (3 papers)Natural product bioactivities and synthesis (2 papers)

In The Last Decade

Eun‐Seok Park

26 papers receiving 497 citations

Peers

Eun‐Seok Park
Comparison fields: 5 of 87
  • Molecular Biology 208
  • Immunology 62
  • Pharmacology 60
  • Surgery 58
  • Oncology 57
Replace Cristina Campos Carraro with:
Cristina Campos Carraro Brazil
Zhenhua Shi China
Sung Yeul Yang South Korea
Yonghui Yu China
Xiaopeng Shi China
So Young Eun South Korea
Guo Zu China
Shaoju Jin China
Jinkun Xi China
Eun‐Seok Park relative to Cristina Campos Carraro Brazil Cristina Campos Carraro's profile →
Citations per field
00.5×1.5×2.5×
Cristina Campos Carraro · 1×
Citations per year

Countries citing papers authored by Eun‐Seok Park

Since Specialization
Citations

This map shows the geographic impact of Eun‐Seok Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eun‐Seok Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eun‐Seok Park more than expected).

Fields of papers citing papers by Eun‐Seok Park

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eun‐Seok Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eun‐Seok Park. The network helps show where Eun‐Seok Park may publish in the future.

Co-authorship network of co-authors of Eun‐Seok Park

This figure shows the co-authorship network connecting the top 25 collaborators of Eun‐Seok Park. A scholar is included among the top collaborators of Eun‐Seok Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eun‐Seok Park. Eun‐Seok Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 3
2 0
3 1
4 15
5 10
6 18
7 10
8 46
9 20
10 39
11 18
12 26
13 17
14 8
15 7
16 6
17 66
18 53
19 48
20
Bioequivalence Evaluation of Aceclofenac Tablets
1

About Eun‐Seok Park

Eun‐Seok Park is a scholar working on Pharmacology, Biochemistry and Immunology, having authored 28 papers that have together received 506 indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (3 papers), Cardiac Ischemia and Reperfusion (3 papers) and Natural product bioactivities and synthesis (2 papers). The work is most often cited by research in Geriatrics and Gerontology (40 citations), Biochemistry (39 citations) and Anesthesiology and Pain Medicine (34 citations). Eun‐Seok Park has collaborated with scholars based in South Korea, United States and Canada. Frequent co-authors include Yeo‐Pyo Yun, Hwan‐Soo Yoo, Yong Lim, Jin‐Tae Hong, Kang Pa Lee, Kyung‐Jong Won, Seung Hyo Jung, Hwa‐Sup Shin, Sang‐Cheol Chi and Kyuhyun Lee. Their work appears in journals such as Sensors, Cardiovascular Research and Experimental Cell Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026